Phenotypic changes of lymphocyte populations in psoriasiform dermatitis animal model

Surcel,Mihaela; Huică,Radu-Ionuț; Munteanu,Adriana   Narcisa; Isvoranu,Gheorghița; Pîrvu,Ioana   Ruxandra; Ciotaru,Dan; Constantin,Carolina; Bratu,Ovidiu; Căruntu,Constantin; Neagu,Monica; Ursaciuc,Cornel

doi:10.3892/etm.2018.6978

Phenotypic changes of lymphocyte populations in psoriasiform dermatitis animal model

Authors:
- Mihaela Surcel
- Radu-Ionuț Huică
- Adriana Narcisa Munteanu
- Gheorghița Isvoranu
- Ioana Ruxandra Pîrvu
- Dan Ciotaru
- Carolina Constantin
- Ovidiu Bratu
- Constantin Căruntu
- Monica Neagu
- Cornel Ursaciuc
View Affiliations

Affiliations: Immunobiology Laboratory, ‘Victor Babeș’ National Institute of Pathology, 050096 Bucharest, Romania, Department of Urology, ‘Carol Davila’ University of Medicine and Pharmacy, 020021 Bucharest, Romania
Published online on: November 16, 2018 https://doi.org/10.3892/etm.2018.6978
Pages: 1030-1038
Copyright: © Surcel et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Psoriasis is a T cell mediated, chronic inflammatory autoimmune skin disease that affects up to 2-3% of the global population and leads to a decrease in quality of life. Experimental data accumulated in recent years highlighted the important role played by the immune system in the pathogenesis of this disease. Non-human psoriasis models are an important research tool that attempts to reproduce the clinical features of the disease in order to explain the pathogenesis of psoriasis and to identify possible therapeutic targets. Imiquimod-based murine model of psoriatic dermatitis is an alternative to traditional models of experimental psoriasis in mice and the induced dermatitis closely mimics the pathologic changes in human psoriasis. In order to emphasize changes in immune cell populations involved in lesion pathogenesis, we performed a murine model of psoriasiform dermatitis model by topical IMQ application. The progress and the severity of IMQ-induced skin inflammation were clinically (PASI score) and histopathologically evaluated. The immunological changes induced by IMQ treatment in lymphocyte populations from peripheral blood and spleen were evaluated by flow cytometry. The main changes observed in peripheral blood were the significantly increased T-CD8a+ lymphocyte and NK1.1+ cell percentages and the decreased T-CD4+ and B lymphocyte percentages in IMQ-treated mice. In spleen samples, lymphocytes showed the same tendency of variation as in peripheral blood, but without statistical significance. A significant decrease of B cells percentages was observed in spleen suspensions. Data obtained in skin samples may suggest the involvement of CD3ε+, CD4+ and CD8a+ cells in the lesional process. This murine model was analyzed by performing a basic cellular profile at three levels: peripheral blood, spleen and skin. The evaluation aimed to establish the immune framework of this experimental model that could further be used for etipathogenic mechanism identification and/or for studies regarding targeted therapies.

View Figures

View References

1	Gudjonsson JE, Ding J, Li X, Nair RP, Tejasvi T, Qin ZS, Ghosh D, Aphale A, Gumucio DL, Voorhees JJ, et al: Global gene expression analysis reveals evidence for decreased lipid biosynthesis and increased innate immunity in uninvolved psoriatic skin. J Invest Dermatol. 129:2795–2804. 2009. View Article : Google Scholar : PubMed/NCBI
2	Parisi R, Symmons DP, Griffiths CE and Ashcroft DM: Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team: Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J Invest Dermatol. 133:377–385. 2013. View Article : Google Scholar : PubMed/NCBI
3	Horn EJ, Fox KM, Patel V, Chiou CF, Dann F and Lebwohl M: Association of patient-reported psoriasis severity with income and employment. J Am Acad Dermatol. 57:963–971. 2007. View Article : Google Scholar : PubMed/NCBI
4	Mease PJ and Armstrong AW: Managing patients with psoriatic disease: The diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs. 74:423–441. 2014. View Article : Google Scholar : PubMed/NCBI
5	Dommasch ED, Li T, Okereke OI, Li Y, Qureshi AA and Cho E: Risk of depression in women with psoriasis: A cohort study. Br J Dermatol. 173:975–980. 2015. View Article : Google Scholar : PubMed/NCBI
6	Ferreira BI, Abreu JL, Reis JP and Figueiredo AM: Psoriasis and associated psychiatric disorders: A systematic review on etiopathogenesis and clinical correlation. J Clin Aesthet Dermatol. 9:36–43. 2016.PubMed/NCBI
7	Kölliker Frers RA, Bisoendial RJ, Montoya SF, Kerzkerg E, Castilla R, Tak PP, Milei J and Capani F: Psoriasis and cardiovascular risk: Immune-mediated crosstalk between metabolic, vascular and autoimmune inflammation. IJC Metab Endocr. 6:43–54. 2015. View Article : Google Scholar
8	Armstrong AW, Harskamp CT and Armstrong EJ: The association between psoriasis and obesity: A systematic review and meta-analysis of observational studies. Nutr Diabetes. 2:e542012. View Article : Google Scholar : PubMed/NCBI
9	Ganguly S, Ray L, Kuruvila S, Nanda SK and Ravichandran K: Lipid accumulation product index as visceral obesity indicator in psoriasis: A case-control study. Indian J Dermatol. 63:136–140. 2018.PubMed/NCBI
10	Cohen AD, Dreiher J, Shapiro Y, Vidavsky L, Vardy DA, Davidovici B and Meyerovitch J: Psoriasis and diabetes: A population-based cross-sectional study. J Eur Acad Dermatol Venereol. 22:585–589. 2008. View Article : Google Scholar : PubMed/NCBI
11	Ahlehoff O, Gislason GH, Lindhardsen J, Charlot MG, Jørgensen CH, Olesen JB, Bretler DM, Skov L, Torp-Pedersen C and Hansen PR: Psoriasis carries an increased risk of venous thromboembolism: A Danish nationwide cohort study. PLoS One. 6:e181252011. View Article : Google Scholar : PubMed/NCBI
12	Ayala-Fontánez N, Soler DC and McCormick TS: Current knowledge on psoriasis and autoimmune diseases. Psoriasis (Auckl). 6:7–32. 2016.PubMed/NCBI
13	Sarac G, Koca TT and Baglan T: A brief summary of clinical types of psoriasis. North Clin Istanb. 3:79–82. 2016.PubMed/NCBI
14	Langley RG and Ellis CN: Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment, and lattice system physician's global assessment. J Am Acad Dermatol. 51:563–569. 2004. View Article : Google Scholar : PubMed/NCBI
15	Finlay AY and Khan GK: Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol. 19:210–216. 1994. View Article : Google Scholar : PubMed/NCBI
16	Mrowietz U and Reich K: Psoriasi - new insights into pathogenesis and treatment. Dtsch Arztebl Int. 106:11–19. 2009.PubMed/NCBI
17	Caruntu C, Boda D, Dumitrascu G, Constantin C and Neagu M: Proteomics focusing on immune markers in psoriatic arthritis. Biomarkers Med. 9:513–528. 2015. View Article : Google Scholar
18	Lande R, Botti E, Jandus C, Dojcinovic D, Fanelli G, Conrad C, Chamilos G, Feldmeyer L, Marinari B, Chon S, et al: The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat Commun. 5:56212014. View Article : Google Scholar : PubMed/NCBI
19	Krueger JG: An autoimmune ‘attack’ on melanocytes triggers psoriasis and cellular hyperplasia. J Exp Med. 212:2186. 2015. View Article : Google Scholar : PubMed/NCBI
20	Benson JM, Sachs CW, Treacy G, Zhou H, Pendley CE, Brodmerkel CM, Shankar G and Mascelli MA: Therapeutic targeting of the IL-12/23 pathways: Generation and characterization of ustekinumab. Nat Biotechnol. 29:615–624. 2011. View Article : Google Scholar : PubMed/NCBI
21	Raţiu MP, Purcărea I, Popa F, Purcărea VL, Purcărea TV, Lupuleasa D and Boda D: Escaping the economic turn down through performing employees, creative leaders and growth driver capabilities in the Romanian pharmaceutical industry. Farmacia. 59:119–130. 2011.
22	Negrei C, Caruntu C, Ginghina O, Dragomiroiu GT, Toderescu CD and Boda D: Qualitative and quantitative determination of methotrexate polyglutamates in erythrocytes by high performance liquid chromatography. Rev Chim. 66:607–610. 2015.
23	Boda D, Negrei C, Nicolescu F and Balalau C: Assessment of some oxidative stress parameters in methotrexate treated psoriasis patients. Farmacia. 62:704–710. 2014.
24	Negrei C, Arsene AL, Toderescu CD, Boda D and Ilie M: Acitretin treatment in oisturiz may influence the cell membrane fluidity. Farmacia. 60:767–771. 2012.
25	Negrei C, Ginghină O, Căruntu C, Burcea Dragomiroiu GT, Jinescu G and Boda D: Investigation relevance of methotrexate polyglutamates in biological systems by high performance liquid chromatography. Rev Chim. 66:766–768. 2015.
26	Olteanu R, Constantin MM, Zota A, Dorobantu DM, Constantin T, Serban ED, Balanescu P, Mihele D and Gheuca-Solovastru L: Original clinical experience and approach to treatment study with interleukine 12/23 inhibitor in moderate-to-severe psoriasis patients. Farmacia. 64:918–992. 2016.
27	Carrascosa JM, Jacobs I, Petersel D and Strohal R: Biosimilar drugs for psoriasis: Principles, present, and near future. Dermatol Ther (Heidelb). 8:173–194. 2018. View Article : Google Scholar : PubMed/NCBI
28	Olteanu R, Zota A and Constantin M: Biosimilars: An update on clinical trials (review of published and ongoing studies). Acta Dermatovenerol Croat. 25:57–66. 2017.PubMed/NCBI
29	Schön MP and Schön M: Imiquimod: Mode of action. Br J Dermatol. 157 Suppl 2:8–13. 2007. View Article : Google Scholar : PubMed/NCBI
30	Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K and Akira S: Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 3:196–200. 2002. View Article : Google Scholar : PubMed/NCBI
31	Urosevic M, Maier T, Benninghoff B, Slade H, Burg G and Dummer R: Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol. 139:1325–1332. 2003. View Article : Google Scholar : PubMed/NCBI
32	Kono T, Kondo S, Pastore S, Shivji GM, Tomai MA, McKenzie RC and Sauder DN: Effects of a novel topical immunomodulator, imiquimod, on keratinocyte cytokine gene expression. Lymphokine Cytokine Res. 13:71–76. 1994.PubMed/NCBI
33	Frotscher B, Anton K and Worm M: Inhibition of IgE production by the imidazoquinoline resiquimod in nonallergic and allergic donors. J Invest Dermatol. 119:1059–1064. 2002. View Article : Google Scholar : PubMed/NCBI
34	Council NR: Guide for the Care and Use of Laboratory Animals. 8th. National Academies Press; Washington, DC: pp. 1–133. 2010
35	van der Fits L, Mourits S, Voerman JS, Kant M, Boon L, Laman JD, Cornelissen F, Mus AM, Florencia E, Prens EP, et al: Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol. 182:5836–5845. 2009. View Article : Google Scholar : PubMed/NCBI
36	Batani A, Brănișteanu DE, Ilie MA, Boda D, Ianosi S, Ianosi G and Caruntu C: Assessment of dermal papillary and microvascular parameters in psoriasis vulgaris using in vivo reflectance confocal microscopy. Exp Ther Med. 15:1241–1246. 2018.PubMed/NCBI
37	Căruntu C, Boda D, Căruntu A, Rotaru M, Baderca F and Zurac S: In vivo imaging techniques for psoriatic lesions. Rom J Morphol Embryol. 55 Suppl 3:1191–1196. 2014.PubMed/NCBI
38	Căruntu C, Boda D, Musat S, Căruntu A and Mandache E: Stress-induced mast cell activation in glabrous and hairy skin. Mediators Inflamm. 2014:1059502014. View Article : Google Scholar : PubMed/NCBI
39	Yamamoto T, Matsuuchi M, Katayama I and Nishioka K: Repeated subcutaneous injection of staphylococcal enterotoxin B-stimulated lymphocytes retains epidermal thickness of psoriatic skin-graft onto severe combined immunodeficient mice. J Dermatol Sci. 17:8–14. 1998. View Article : Google Scholar : PubMed/NCBI
40	Boehncke WH, Zollner TM, Dressel D and Kaufmann R: Induction of psoriasiform inflammation by a bacterial superantigen in the SCID-hu xenogeneic transplantation model. J Cutan Pathol. 24:1–7. 1997. View Article : Google Scholar : PubMed/NCBI
41	Wohn CT, Pantelyushin S, Ober-Blöbaum JL and Clausen BE: Aldara-induced psoriasis-like skin inflammation: Isolation and characterization of cutaneous dendritic cells and innate lymphocytes. Methods Mol Biol. 1193:171–185. 2014. View Article : Google Scholar : PubMed/NCBI
42	Lundberg KC, Fritz Y, Johnston A, Foster AM, Baliwag J, Gudjonsson JE, Schlatzer D, Gokulrangan G, McCormick TS, Chance MR, et al: Proteomics of skin proteins in psoriasis: From discovery and verification in a mouse model to confirmation in humans. Mol Cell Proteomics. 14:109–119. 2015. View Article : Google Scholar : PubMed/NCBI
43	Neagu M, Constantin C and Zurac S: Immune parameters in the prognosis and therapy monitoring of cutaneous melanoma patients: Experience, role, and limitations. Biomed Res Int. 2013:1079402013. View Article : Google Scholar : PubMed/NCBI
44	Manda G, Neagu M, Livescu A, Constantin C, Codreanu C and Radulescu A: Imbalance of peripheral B lymphocytes and NK cells in rheumatoid arthritis. J Cell Mol Med. 7:79–88. 2003. View Article : Google Scholar : PubMed/NCBI
45	Singh K, Gatzka M, Peters T, Borkner L, Hainzl A, Wang H, Sindrilaru A and Scharffetter-Kochanek K: Reduced CD18 levels drive regulatory T cell conversion into Th17 cells in the CD18hypo PL/J mouse model of psoriasis. J Immunol. 190:2544–2553. 2013. View Article : Google Scholar : PubMed/NCBI
46	Prinz I and Sandrock I: γδ T cells come to stay: Innate skin memory in the Aldara model. Eur J Immunol. 45:2994–2997. 2015. View Article : Google Scholar : PubMed/NCBI